Marker for use in identifying or predicting diseases of the macula

DARC with angular plot analysis addresses the need for early diagnosis and prediction of macular diseases by assessing stressed cells in the retina, providing accurate identification and staging of macular diseases and predicting atrophy direction and severity.

WO2026234039A1PCT designated stage Publication Date: 2026-11-12NOVAI LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/062998
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-05
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current methods lack effective tools for early diagnosis and prediction of macular diseases, particularly those leading to irreversible macular atrophy, and there is a need for additional diagnostic indicators beyond the Ellipsoid zone (EZ) integrity.

Method used

The use of DARC (Detection of Apoptosing Retinal Cells) with angular plot analysis to assess the arrangement of stressed cells, such as RPEs and photoreceptors, in the retina to identify, predict, stage, or prognosticate macular diseases, utilizing fluorescently labelled Annexin A5 to detect apoptosis and apoptosis markers like Annexin A5, Annexin 11, 2, or 6, and other apoptotic markers.

Benefits of technology

DARC with angular plot analysis provides accurate identification, prediction, and staging of macular diseases, allowing for early intervention and monitoring of disease progression, offering a more precise prediction of atrophy direction and severity than existing methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2026062998_12112026_PF_FP_ABST
    Figure EP2026062998_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Methods of identifying, predicting, staging or prognosticating a disease of the macula in a subject, comprising identifying stressed cells in an image of the retina of a subject and assessing the arrangement of the one or more labelled cell stress marker positive cells using angular plot analysis.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] MARKER FOR USE IN IDENTIFYING OR PREDICTING DISEASES OF THE MACULA TECHNICAL FIELD

[0002] This invention relates to a labelled cell stress marker for use in identifying, predicting, staging or prognosticating geographic atrophy (GA) and other diseases of the macula in a subject. The invention also relates to methods of identifying, predicting, staging or prognosticating diseases of the macula in a subject. Such methods may also include the step of treating any disease identified, predicted or staged. The invention further relates to methods of monitoring the effect of treatment of one or more diseases of the macula in a subject. It also relates to treatments of one or more diseases of the macula, wherein the diseases have been identified by the methods of the invention.

[0003] BACKGROUND

[0004] Age-related macular degeneration (AMD) is a leading cause of visual impairment and irreversible blindness in the elderly population worldwide. It is estimated to increase to 288 million in 2040, approximately 8.7% of global blindness. Although AMD may present in different stages, the endpoint of AMD is macular atrophy (MA), which is irreversible and characterized by the permanent loss of photoreceptors, RPE (retinal pigment epithelium), and the underlying choriocapillaris. It can be seen in advanced dry and wet AMD, with at least 20% of patients with treated wet AMD showing conversion to MA after 1-2 years. Early detection of MA is crucial to avoid onset of vision loss, especially as new treatments are emerging with two therapies having recently been approved in the USA.

[0005] The Ellipsoid zone (EZ) is a distinct hyperreflective striped-band in OCT images representing mitochondria in photoreceptor inner segments. Loss of EZ indicates photoreceptor death after they have already lost function and structure. EZ is now a recognized endpoint for monitoring disease progression and evaluating therapeutic response. Photoreceptor loss (the loss of EZ) typically occurs beyond regions of MA. Photoreceptor degeneration (loss or thinning) has been proven to predict future or subsequent MA progression in patients with AMD, and following on from the results of the ReCLAIM-2 Clinical Trial (NCT03891875), the FDA has recently confirmed EZ attenuation as an approvable surrogate endpoint in dry AMD for predicting MA. However, it would be advantageous to provide other end points or diagnostic indicators for diseases of the macula, especially any that can provide an early indication of macular disease that could lead to MA.Another important feature frequently observed during progression to MA is the presence of hyperreflective foci (HRF), a subclinical biomarker that can be identified on OCT images, characterized by small, dot-shaped lesions with equal or higher reflectivity than RPE. The formation of HRF is widely attributed to the migration and / or apoptosis of RPE cells overlying drusen into the neurosensory retina during disease progression, a process that ultimately leads to drusen collapse. More recent studies suggest that increased HRF in the junctional zone adjacent to baseline atrophy reflect ongoing RPE migration and are predictive of subsequent RPE loss (atrophy).

[0006] Detection of Apoptosing Retinal Cells (DARC) is a retinal imaging technology to detect live stress and apoptosis at a cellular level in retina cells using ANX776 (fluorescently labelled Annexin A5). DARC has shown potential in various retinal and neurodegenerative conditions including glaucoma, optic neuropathy, AMD, Alzheimer’s, Parkinson’s, and Diabetes.

[0007] Recently, there has been growing interest in utilising the integrity of the EZ for predicting future MA development. Whilst EZ integrity is commonly used to estimate MA growth, its ability to predict the direction of this growth remains largely unexplored. There remains a need for tools to assist with early diagnosis and prediction of disease severity, though.

[0008] SUMMARY OF THE INVENTION

[0009] The inventors identified that DARC could be a valuable biomarker for wet AMD, indicating early endothelial angiogenic activity. A further analysis of AMD patients with MA showed that DARC activity at baseline was predictive of final MA growth up to 36 months later, and eyes with a DARC count greater than 10 at the macula were shown to have a significantly greater rate of MA expansion.

[0010] The inventors investigated apoptosis in the eyes of rats with retinal atrophy using DARC and identified that apoptosis generally occurred in a ring around the edge of the atrophy, often some distance from the edge of the actual atrophy. There is no macula in rat eyes, but the inventors questioned whether it would be possible to connect such remote apoptosis with atrophy in humans, particularly in the macula and foveal center. The inventors then sought to investigate whether DARC could be indicative or predictive of macular disease, and whether particular analysis methods are useful in providing such indications or predictions. The inventors have surprisingly found that DARC can be used to provide diagnostic and predictive information about macular disease and that angular plot analysis enables a clearand comprehensive assessment of both directional and overall expansion of atrophy in the macula.

[0011] According to a first aspect of the invention, there is provided a method of identifying, predicting, staging or prognosticating a disease of the macula in a subject, the method comprising the steps of:

[0012] providing a first image of the retina of a subject to whom a labelled cell stress marker has been administered;

[0013] identifying one or more labelled cell stress marker positive cells in that image;

[0014] and assessing the arrangement of the one or more labelled cell stress marker positive cells using angular plot analysis.

[0015] The inventors have found that using angular plot analysis to assess the arrangement of stressed cells in the retina allows them to accurately identify, predict, stage or prognosticate the disease of the macula. The method may include the step of relating the arrangement of stressed cells in the retina allows them to accurately identify, predict, stage or prognosticate the disease of the macula.

[0016] As used herein, the term “labelled cell stress marker positive cells” refers to one or more cells to which a labelled cell stress marker is bound. It generally refers to cells that are stressed and can be used interchangeably herein with the term “stressed cells”.

[0017] As used herein, the term “stressed cells” refers to a cell undergoing stress, such as a cell that is capable of, or is undergoing apoptosis. It can also refer to a cell involved in angiogenesis. The term can be used interchangeably with the term “labelled cell stress marker positive cells”.

[0018] The stressed cells may be any cells that undergo stress in macular diseases, for example cells that are apoptosing or dead, or cells involved in angiogenesis. For example, the cells may be one or more of RPEs and photoreceptors, particularly photoreceptors.

[0019] As used herein, the term “assessing the arrangement of the one or more labelled cell stress marker positive cells” refers to identifying or otherwise considering the number and / or position of the one or more labelled cell stress marker positive cells, for example in relation to a known point in the retina, or to other cells, particularly to other stressed cells. For example, it may refer to identifying the position of one or more stressed cells in relation to the macula, or to the EZ.As used herein, the term "cell stress marker" refers to a marker that identifies cells undergoing cell stress. Thus, the marker may be known as a compound or molecule that specifically binds to stressed cells. The cell stress may be predictive of the cell ultimately undergoing apoptosis. In some embodiments, the cell stress marker is also capable of labelling apoptosing cells (i.e. , the marker is capable of labelling cells undergoing cell stress, as well as apoptosing cells). Thus, in embodiments, the cell stress marker may be referred to herein as an "apoptosis marker".

[0020] As used herein, the term "apoptosis marker" refers to a marker that allows cells undergoing apoptosis to be distinguished from live cells. The marker may also be able to distinguish apoptosing cells from necrotic cells. Thus, the marker may be known as a compound or molecule that specifically binds to apoptotic cells.

[0021] The cell stress marker may comprise or consist of a marker that identifies stressed cell membranes.

[0022] The term "disease of the macula" refers to diseases in which there is cell death in the macula, particularly in which there is macula atrophy. It may be used interchangeably herein with the term “macular disease”. Such diseases include but are not limited to Age-related Macular Degeneration (AMD), Stargardt Disease, Best Disease (Best Vitelliform Macular Dystrophy), Macular Telangiectasia Type 2 (MacTel 2), Cone-Rod Dystrophy, Pattern Dystrophies, Geographic Atrophy (GA), Chronic Central Serous Chorioretinopathy, Choroideremia, Gyrate Atrophy, Toxin based diseases such as Thioridazine Toxicity and Hydroxychloroquine Toxicity, and Advanced Retinitis Pigmentosa.

[0023] In an embodiment, the disease is AMD. In an embodiment, the disease is GA.

[0024] The expression "predicting a disease of the macula” may be understood to refer to a prediction of a disease of the macula, before it has occurred, or at such an early stage of disease that the subject is asymptomatic and / or the disease would not otherwise be identified, for example before an identifiable lesion has formed.

[0025] The expression "identifying a disease of the macula " may be understood to refer to an identification or diagnosis of a disease of the macula.

[0026] The expression "staging a disease of the macula" may be understood to refer to providing an indication or understanding of the stage of development or seriousness of a disease of the macula.The expression "prognosticating a disease of the macula " may be understood to refer to predicting the likely outcome or seriousness of a disease of the macula, for example, predicting how quickly a lesion will develop or how soon a subject’s sight will be affected. It may include predicting the direction of growth of atrophy.

[0027] Advantageously, the ability to predict a particular disease, stage of disease and / or disease severity, or to identify a particular disease at an early stage, allows the most suitable treatment course to be selected, administered and, optionally, monitored.

[0028] In some embodiments, the cell stress marker is an annexin or a fragment or variant thereof. The annexin family of proteins are known apoptotic markers. Annexins are proteins that bind reversibly to cellular membranes in the presence of cations. Annexins useful in the invention may be natural or may be recombinant.

[0029] By "fragment" this will be understood to refer to a truncated version of an annexin that substantially retains the functional activity of the whole annexin. By "substantially retains", this will be understood to refer to a functional activity of at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98% or at least 99% of the whole annexin. A variant of an annexin will be understood to refer to a protein which has an amino acid sequence that varies from the wild type annexin, such that the variant has at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98% or at least 99% sequence identity to the wild type annexin. A variant of an annexin will substantially retain the functional activity of the wild type annexin.

[0030] The annexin may be annexin 5, 11, 2 or 6. In some embodiments, the annexin is annexin 5. In another embodiment, the annexin is annexin 128. Annexin 128 is a variant of annexin 5 and differs from the wild-type annexin 5 by two single amino acid mutations. Annexin 128 includes an exposed thiol group at the N-terminus, which affords increased conjugation efficiency for molecular tags, such as fluorescent labels.

[0031] Without being bound by theory, the present inventors believe that phosphatidylserine, to which annexin is capable of binding, is exposed in stressed endothelial cells. Therefore, the identification of phosphatidylserine, for example by the binding of annexin, can indicate cell stress. Other apoptosis markers are known in the art including, for example C2A domain of synaptotagmin-I, duramycin, non-peptide based isatin sulfonamide analogs, such as WC- 11-89, and ApoSense, such as NST-732, DDC and ML-10. Such apoptotic markers are suitable for use as cell stress markers of the present invention.The label of the cell stress marker may be visible. Exemplary visible labels may include, but not necessarily be limited to quantum dots, nanospheres and / or nanorods. Other visible labels will be known to the skilled person.

[0032] The label may be fluorescent. Fluorescent labels refer to compounds or molecules (such as fluorophores) which emit light in response to excitation, and which may be selected for use due to increased signal-to noise ratio and thereby improved image resolution and sensitivity while adhering to light exposure safety standards to avoid phototoxic effects. It is preferred that the fluorescent label causes little or no inflammation on administration. The fluorescent label may have a wavelength in the infra-red or near infra-red spectrum. The fluorescent label may have an emission wavelength of about 400nm to about lOOOnm, preferably about 500nm to about 900nm, more preferably about 700nm to about 900nm.

[0033] Suitable fluorescent labels include one or more of sodium fluorescein, indocyanine green (ICG), curcumin, IRDye700, Dy-776 (which may otherwise be referred to as D-776), Dy-488 and Dy-781. In some embodiments the fluorescent label is D-776.

[0034] The labelled cell stress marker may be prepared using standard techniques for conjugating a label, for example a fluorescent label, to a marker compound. Such labels may be obtained from well-known sources such as Dyomics. Appropriate techniques for conjugating the label to the marker are known in the art and may be provided by the manufacturer of the label. In some embodiments, the subject is a mammal. For example, the subject may be a rat, mouse, human, rabbit, horse, dog, cat, cow or sheep. In some embodiments, the subject is selected from a mouse, rat, human and rabbit. In some embodiments, the subject is human. In the method, the disease may be identified, predicted, staged or prognosticated, based on the number and / or position of stressed cells, for example the number of stressed cells within a certain proximity to a particular part of the retina, such as the macula.

[0035] The term “angular plot analysis” is known in the art. It is a method used to interpret data that involves directional or angular measurements.

[0036] An angular plot displays values as a function of angle, typically using circular coordinates. Angular plot analysis refers to the process of evaluating patterns, trends, or distributions in this angular data.The method may comprise the step of preparing or obtaining directional data about the one or more stressed cells identified. In particular, this step may comprise identifying the location, particularly the angular location of the stressed cells, in relation to a particular analysis point. The method may comprise the step of dividing the whole or part of the image of the retina into a plurality of segments and identifying the one or more stressed cells in each segment. The part of the image divided into segments will generally be circular, with the segments being angular segments arranged around a particular analysis point. The segments are generally of equal size. The segments may generally be 30°, 29°, 28°, 27°, 26°, 25°, 24°, 23°, 22°, 21°, 20°, 19°, 18°, 17°, 16°, 15°, 14°, 13°, 12°, 11°, 10°, 9°, 8°, 7°, 6°, 5°, 4°, 3.0°, 2.9°, 2.8°, 2.7°, 2.6°, 2.5°, 2.4°, 2.3°, 2.2°, 2.1°, 2.0°, 1.9°, 1.8°, 1.7°, 1.6°, 1.5°, 1.4°, 1.3°, 1.2°, 1.1°, 1.0°, 0.9°, 0.8°, 0.7°, 0.6°, 0.5°, 0.4°, 0.3°, 0.2°, or 0.1° or less in size. In an embodiment, the segments are around 3.0°, 2.0°, 1.0° or less in size.

[0037] The analysis point may be, for example, a lesion that has been identified. Alternatively, it may be a particular point on the retina, such as part of the macula, such as the fovea, especially the fovea centralis.

[0038] The method may comprise the step of totalling the number of stressed cells in each segment. The method may comprise the step of plotting the total number of stressed cells in each segment in an angular plot.

[0039] The methods may comprise the step of analysing the number and arrangement of segments in which stressed cells are found.

[0040] The method may comprise the step of assessing the number of stressed cells in particular segments, for example adjacent segments, or segments that are within a small number of segments in which one or more stressed cell is found.

[0041] The method may comprise the step of generating an image from the subject using an imaging device.

[0042] The method may comprise the step of administering a labelled cell stress marker to the subject.

[0043] Administration of the labelled cell stress marker may be intravenous, intranasal, topical or intravitreal. By topical, this will be understood to refer to application to the surface of the subject, for example, to the skin or to the surface of the eye. In some embodiments, thelabelled cell stress marker is administered intravenously. In other embodiments, the labelled cell stress marker is administered intravitreally.

[0044] In some embodiments, the method further comprises administering an appropriate treatment for the disease, stage of disease, severity of disease or predicted disease identified.

[0045] A suitable treatment for AMD and / or for GA may comprise or consist of AREDS2 supplements, pegcetacoplan (Syfovre), and / or avacincaptad pegol (Izervay), gene therapy, stem cell or other cellular therapy, and / or complement pathway inhibitors.

[0046] A suitable treatment for Stargardt Disease may comprise or consist of gene therapy, stem cell therapy, and / or visual cycle modulators such as emixustat.

[0047] A suitable treatment for Best Disease may comprise or consist of anti-VEGF compositions such as ranibizumab, aflibercept, brolucizumab, bevacizumab, and faricimab.

[0048] A suitable treatment for MacTel 2 may comprise or consist of anti-VEGF compositions such as CNTF (ciliary neurotrophic factor) implants and / or stem cell therapy.

[0049] A suitable treatment for Cone-Rod Dystrophy may comprise or consist of gene therapy and retinal implants.

[0050] A suitable treatment for Pattern Dystrophies may comprise or consist of anti-VEGF compositions such as ranibizumab, aflibercept, brolucizumab, bevacizumab, and faricimab. A suitable treatment for Chronic Central Serous Chorioretinopathy may comprise or consist of Photodynamic therapy (PDT), micropulse laser therapy, and / or mineralocorticoid receptor antagonists such as eplerenone and spironolactone.

[0051] A suitable treatment for Choroideremia may comprise or consist of REP 1 gene replacement. A suitable treatment for Gyrate Atrophy may comprise or consist of Vitamin B6 (pyridoxine) supplementation.

[0052] A suitable treatment for Advanced Retinitis Pigmentosa may comprise or consist of vitamin A palmitate, retinal implants such as Argus II, gene therapy, stem cell or other cellular therapy.

[0053] Administration of the appropriate treatment may be, for example, intravenous, intranasal, topical or intravitreal.

[0054] In some embodiments, identifying labelled cell stress marker positive cell(s) comprises determining the location of labelled cell stress marker positive cell(s) in the subject. This maycomprise determining the anatomical location of labelled cell stress marker positive cell(s) shown in the image. As mentioned previously, the cell stress marker of the invention may label both cells undergoing stress and apoptosing cells. Accordingly, it may be desirable to distinguish between apoptosing and stressed cells or between apoptosing cells and those involved in angiogenesis, or between stressed cells of different types, e.g., RPE cells and microglia. The inventors have identified that one way of achieving this is to look at the location of the marked cell and consider whether it is in in a location where angiogenesis is likely to be taking place, for example near to a blood vessel, or if it is somewhere angiogenesis is unlikely to occur, e.g. in the photoreceptor layer of the retina. Alternatively, or additionally, it may be helpful to consider in which layer of the retina the labelled cells are found, as this can help in distinguishing cell types. The methods of the invention may therefore further comprise the step of determining the location of the cell stress marker positive cell(s), the location being indicative of whether the cell is involved in angiogenesis or is otherwise stressed, or of the cell type. The step of determining the location of the cell stress marker positive cell may comprise identifying the location of the cell relative to an anatomical structure, such as a blood vessel, or tissue type, or its location in a particular layer of the retina.

[0055] The step of determining the location may comprise identifying the location of the cell on the first image generated. Alternatively, it may comprise locating the cell in an additional image, referred to herein as a “location image”, particularly an image showing the cell from a different aspect, or showing tissues or other structures that may not be visible in the first image. Optionally, the method comprises determining the location of labelled cell stress marker positive cell(s) in a plurality of planes. For example, the location of labelled cell stress marker positive cell(s) may be determined across an x axis and a y axis, e.g. in a 2D image. The location of labelled cell stress marker positive cell(s) may be determined across an x axis, a y axis and a z axis. In some embodiments, the location of the cell may be identified from a plurality of images. For example, the location of the cell may be identified using at least a second and third image. Each of the plurality of images may be taken using a similar or identical frame of reference, so that after the plurality of images are obtained, they can be stacked together to form a x, y and z axis. In other words, to form a 3D image. The 3D image can be used to identify the location of the cell.

[0056] The method may comprise generating a location image of the subject, for example using the same or a different imaging device, and, optionally comparing that image with the firstimage. Where the method comprises comparing one or more images, it is preferable that one image may be overlaid on the other. The method may comprise the step of doing so. It may also comprise the step of image registration, i.e. aligning the images, to correctly match up the cell stress marker positive cells shown in each image.

[0057] Where the method comprises the use of at least one location image, the location image may be obtained using the same or different imaging device to the first. For example, a first imaging device may comprise or consist of confocal scanner laser microscope. An example of a confocal scanner laser microscope is a confocal scanning laser ophthalmoscope (cSLO). In some embodiments a first and a second imaging device are used to obtain the first and location images. The second imaging device may comprise or consist of a computerized tomography (CT) scanner, a magnetic resonance imaging (MRI) scanner, a position emission tomography (PET) scanner, a polariser, a reflective image scanner, fundus camera and / or an OCT scanner. In an embodiment, the second imaging device is a different device to the first imaging device.

[0058] In some embodiments, the second imaging device comprises or consists of a computerized tomography (CT) scanner, a magnetic resonance imaging (MRI) scanner, a position emission tomography (PET) scanner, and / or an OCT scanner.

[0059] In some embodiments, the second imaging device comprises or consists of an OCT scanner. In some embodiments, first, second and third imaging devices are used to obtain the first image and two or more location images. The third imaging device may comprise or consist of a computerized tomography (CT) scanner, a magnetic resonance imaging (MRI) scanner, a position emission tomography (PET) scanner, polariser, reflective image scanner, fundus camera and / or an OCT scanner. Preferably, the third imaging device is a different device to the first and second imaging device.

[0060] A first imaging device may be used to obtain a 2D or 3D image. Optionally, the first imaging device is used to obtain a 2D image. A second imaging device may be used to obtain a 2D or 3D image. The second imaging device may be used to obtain a 3D image. In some embodiments, a second or third imaging device is used to provide a mask image. By mask image, this will be understood to refer to a "background" image, i.e. an image that can be used to set a background value for the image which is used to identify the location of the cell. In some embodiments, the third imaging device comprises or consists of a reflective image scanner.In one embodiment, the method comprises determining the location of one or more blood vessel(s). Determination of the location of the blood vessels may be by angiography, methods for which are known in the art. For example, the location of the blood vessels may be determined using Fluorescein angiography (FA), indocyanine green angiography (ICGA), and / or optical coherence tomography (OCT), optionally optical coherence tomography angiography (OCTA).

[0061] In some embodiments, determining the location of labelled cell stress marker positive cell(s) in the image may comprise determining the location of said cells relative to the location of blood vessel(s).

[0062] One or more of: the step of identification of labelled cell stress marker positive cell(s); the step of angular plot analysis; and the step of locating the labelled cell stress marker positive cell(s) in the image may be computer-implemented. This may comprise generating training data for use in training an identification model, such as an artificial neural network. The artificial neural network may comprise a convolutional neural network (CNN). The training data may comprise control data manually classified as comprising or not comprising labelled cell stress marker positive cell(s), for example, from subjects already known to have (or not have) a disease, for example dry-AMD, wet- AMD or GA. In some embodiments, an identification model may be trained using training data. This may be in addition to or instead of a step of generating training data for use in training an identification model. Once trained, the identification model may be validated manually.

[0063] A trained identification model (such as, for example, a convolutional neural network), may be used to identify labelled cell stress marker positive cell(s) and optionally the location of labelled cell stress marker positive cell(s). It may also be used to segment the image, and / or total the number of cells in a segment, and / or generate an angular plot of those totals, and / or analyse the number and arrangement of segments in which stressed cells are found.

[0064] Alternatively, the identification of labelled cell stress marker positive cell(s), and optionally the location of labelled cell stress marker positive cell(s) in the image, including the steps of segmenting the imaging and identifying and analysing the number or arrangement of stressed cells and / or the segments in which they are found, may be manual.

[0065] In some embodiments, the identification of at least 5, at least 10, at least 15, at least 20, at least 30 or at least 40 labelled cell stress marker positive cells in the image, within a certain distance of an area of interest, such as the macula and particularly the fovea, is indicative orpredictive of the subject having or developing a disease of the macula, or indicative of the severity of that disease. In some embodiments, the identification of at least 5, at least 10, at least 15, at least 20, at least 30 or at least 40 labelled cell stress marker positive cells in the image, within about 1.00pm, 0.99pm, 0.98pm, 0.97pm, 0.96pm, 0.95pm, 0.94pm, 0.93pm, 0.92pm, 0.91pm, 0.90pm, 0.89pm, 0.88pm, 0.87pm, 0.86pm, 0.85pm, 0.84pm, 0.83pm, 0.82pm, 0.81pm, 0.80pm, 0.79pm, 0.78pm, 0.77pm, 0.76pm, 0.75pm, 0.74pm, 0.73pm, 0.72pm, 0.71pm, 0.70pm, 0.69pm, 0.68pm, 0.67pm, 0.66pm, 0.65pm, 0.64pm, 0.63pm, 0.62pm, 0.61pm, 0.60pm, 0.59pm, 0.58pm, 0.57pm, 0.56pm, 0.55pm, 0.54pm, 0.53pm, 0.52pm, 0.51pm, 0.50pm, 0.49pm, 0.48pm, 0.47pm, 0.46pm, 0.45pm, 0.44pm, 0.43pm, 0.42pm, 0.41pm, 0.40pm, 0.39pm, 0.38pm, 0.37pm, 0.36pm, 0.35pm, 0.34pm, 0.33pm, 0.32pm, 0.31pm, 0.30pm, 0.29pm, 0.28pm, 0.27pm, 0.26pm, 0.25pm, 0.24pm, 0.23pm, 0.22pm, 0.21pm, 0.20pm, 0.19pm, 0.18pm, 0.17pm, 0.16pm, 0.15pm, 0.14pm, 0.13pm, 0.12pm, 0.11pm, 0.10pm, 0.09pm, 0.08pm, 0.07pm, 0.06pm, 0.05pm, 0.04pm, 0.03pm, 0.02pm, 0.01pm of the macula and particularly the fovea is predictive of the subject having or developing a disease of the macula and / or of the severity of that disease.

[0066] Advantageously, the present inventors have also found that an increasing number of labelled cell stress marker positive cells identified within a certain distance of an area of interest, such as the macula, correlates with the severity of disease that subsequently develops, i.e., the higher the number of identified labelled cell stress marker positive cells within that distance, the greater the severity of disease which will subsequently occur. Thus, in some embodiments, the identification of at least 10, at least 15, at least 20, at least 30 or at least 40 labelled cell stress marker positive cells within a certain distance of an area of interest is predictive of the subject developing an increased severity of disease. In some embodiments, the identification of at least 5, at least 10, at least 15, at least 20, at least 30 or at least 40 labelled cell stress marker positive cells in the image, within about 1.00pm, 0.99pm, 0.98pm, 0.97pm, 0.96pm, 0.95pm, 0.94pm, 0.93pm, 0.92pm, 0.91pm, 0.90pm, 0.89pm, 0.88pm, 0.87pm, 0.86pm, 0.85pm, 0.84pm, 0.83pm, 0.82pm, 0.81pm, 0.80pm, 0.79pm, 0.78pm, 0.77pm, 0.76pm, 0.75pm, 0.74pm, 0.73pm, 0.72pm, 0.71pm, 0.70pm, 0.69pm, 0.68pm, 0.67pm, 0.66pm, 0.65pm, 0.64pm, 0.63pm, 0.62pm, 0.61pm, 0.60pm, 0.59pm, 0.58pm, 0.57pm, 0.56pm, 0.55pm, 0.54pm, 0.53pm, 0.52pm, 0.51pm, 0.50pm, 0.49pm, 0.48pm, 0.47pm, 0.46pm, 0.45pm, 0.44pm, 0.43pm, 0.42pm, 0.41pm, 0.40pm, 0.39pm, 0.38pm, 0.37pm, 0.36pm, 0.35pm, 0.34pm, 0.33pm, 0.32pm, 0.31pm, 0.30pm, 0.29pm, 0.28pm, 0.27pm, 0.26pm, 0.25pm, 0.24pm, 0.23pm, 0.22pm, 0.21pm, 0.20pm, 0.19pm, 0.18pm,0.17pm, 0.16pm, 0.15pm, 0.14pm, 0.13pm, 0.12pm, 0.11pm, 0.10pm, 0.09pm, 0.08pm, 0.07pm, 0.06pm, 0.05pm, 0.04pm, 0.03pm, 0.02pm, 0.01pm of the macula and particularly the fovea is having, or developing a disease of the macula, and / or of having an increased severity of disease.

[0067] In an embodiment, the method comprises the step of identifying at least 5, at least 10, at least 15, at least 20, at least 30 or at least 40 labelled cell stress marker positive cells in the image, within about 1.00pm, 0.99pm, 0.98pm, 0.97pm, 0.96pm, 0.95pm, 0.94pm, 0.93pm, 0.92pm, 0.91pm, 0.90pm, 0.89pm, 0.88pm, 0.87pm, 0.86pm, 0.85pm, 0.84pm, 0.83pm, 0.82pm, 0.81pm, 0.80pm, 0.79pm, 0.78pm, 0.77pm, 0.76pm, 0.75pm, 0.74pm, 0.73pm, 0.72pm, 0.71pm, 0.70pm, 0.69pm, 0.68pm, 0.67pm, 0.66pm, 0.65pm, 0.64pm, 0.63pm, 0.62pm, 0.61pm, 0.60pm, 0.59pm, 0.58pm, 0.57pm, 0.56pm, 0.55pm, 0.54pm, 0.53pm, 0.52pm, 0.51pm, 0.50pm, 0.49pm, 0.48pm, 0.47pm, 0.46pm, 0.45pm, 0.44pm, 0.43pm, 0.42pm, 0.41pm, 0.40pm, 0.39pm, 0.38pm, 0.37pm, 0.36pm, 0.35pm, 0.34pm, 0.33pm, 0.32pm, 0.31pm, 0.30pm, 0.29pm, 0.28pm, 0.27pm, 0.26pm, 0.25pm, 0.24pm, 0.23pm, 0.22pm, 0.21pm, 0.20pm, 0.19pm, 0.18pm, 0.17pm, 0.16pm, 0.15pm, 0.14pm, 0.13pm, 0.12pm, 0.11pm, 0.10pm, 0.09pm, 0.08pm, 0.07pm, 0.06pm, 0.05pm, 0.04pm, 0.03pm, 0.02pm, 0.01pm of the macula and particularly the fovea.

[0068] The inventors have found that the distance between stressed cells and the area of interest can be larger than would be expected from existing methods of diagnosis (e.g., from areas of the EZ). Without being bound by theory, it is possible that apoptosing cells can be identified by DARC in a ring around the macula, before any impact on the EZ is seen. The stressed cells tend to be found in the direction of, or surrounding an area of disease. The presence of stressed cells in the area around the macula can be used not only to identify or predict the presence of macular disease, but also to predict how that disease will develop, in particular the likely direction of growth of any atrophy. For example, the presence of, or the concentration of stressed cells in a particular segment or segments, or in a number of adjacent or nearby segments may be used to predict the direction of the growth of disease, with atrophy being predicted to grow in the direction, particularly the angular direction, of those stressed cells. The inventors have also found that the method of the invention provides a significantly more accurate result than previous methods (e.g., use of the EZ or HRF).

[0069] In some embodiments, the identification of at least 5, at least 10, at least 15, at least 20, at least 30 or at least 40 labelled cell stress marker positive cells in the image, at about or up to or at least 0.01pm, 0.02pm, 0.03pm, 0.04pm, 0.05pm, 0.06pm, 0.07pm, 0.08pm, 0.09pm,0.10pm, 0.11pm, 0.12pm, 0.13pm, 0.14pm, 0.15pm, 0.16pm, 0.17pm, 0.18pm, 0.19pm, 0.20pm, 0.21pm, 0.22pm, 0.23pm, 0.24pm, 0.25pm, 0.26pm, 0.27pm, 0.28pm, 0.29pm, 0.30pm, 0.31pm, 0.32pm, 0.33pm, 0.34pm, 0.35pm, 0.36pm, 0.37pm, 0.38pm, 0.39pm, 0.40pm, 0.41pm, 0.42pm, 0.43pm, 0.44pm, 0.45pm, 0.46pm, 0.47pm, 0.48pm, 0.49pm, 0.50pm, 0.51pm, 0.52pm, 0.53pm, 0.54pm, 0.55pm, 0.56pm, 0.57pm, 0.58pm, 0.59pm, 0.60pm, 0.61pm, 0.62pm, 0.63pm, 0.64pm, 0.65pm, 0.66pm, 0.67pm, 0.68pm, 0.69pm, 0.70pm, 0.71pm, 0.72pm, 0.73pm, 0.74pm, 0.75pm, 0.76pm, 0.77pm, 0.78pm, 0.79pm, 0.80pm, 0.81pm, 0.82pm, 0.83pm, 0.84pm, 0.85pm, 0.86pm, 0.87pm, 0.88pm, 0.89pm, 0.90pm, 0.91pm, 0.92pm, 0.93pm, 0.94pm, 0.95pm, 0.96pm, 0.97pm, 0.98pm, 0.99pm, 1.00pm from the macula and particularly the fovea is predictive of the subject having, or developing a disease of the macula, and / or of having an increased severity of disease.

[0070] Accordingly, the method may comprise the step of identifying of at least 5, at least 10, at least 15, at least 20, at least 30 or at least 40 labelled cell stress marker positive cells in the image, at about or up to or at least 0.01pm, 0.02pm, 0.03pm, 0.04pm, 0.05pm, 0.06pm, 0.07pm, 0.08pm, 0.09pm, 0.10pm, 0.11pm, 0.12pm, 0.13pm, 0.14pm, 0.15pm, 0.16pm, 0.17pm, 0.18pm, 0.19pm, 0.20pm, 0.21pm, 0.22pm, 0.23pm, 0.24pm, 0.25pm, 0.26pm, 0.27pm, 0.28pm, 0.29pm, 0.30pm, 0.31pm, 0.32pm, 0.33pm, 0.34pm, 0.35pm, 0.36pm, 0.37pm, 0.38pm, 0.39pm, 0.40pm, 0.41pm, 0.42pm, 0.43pm, 0.44pm, 0.45pm, 0.46pm, 0.47pm, 0.48pm, 0.49pm, 0.50pm, 0.51pm, 0.52pm, 0.53pm, 0.54pm, 0.55pm, 0.56pm, 0.57pm, 0.58pm, 0.59pm, 0.60pm, 0.61pm, 0.62pm, 0.63pm, 0.64pm, 0.65pm, 0.66pm, 0.67pm, 0.68pm, 0.69pm, 0.70pm, 0.71pm, 0.72pm, 0.73pm, 0.74pm, 0.75pm, 0.76pm, 0.77pm, 0.78pm, 0.79pm, 0.80pm, 0.81pm, 0.82pm, 0.83pm, 0.84pm, 0.85pm, 0.86pm, 0.87pm, 0.88pm, 0.89pm, 0.90pm, 0.91pm, 0.92pm, 0.93pm, 0.94pm, 0.95pm, 0.96pm, 0.97pm, 0.98pm, 0.99pm, 1.00pm from the macula and particularly the fovea.

[0071] In some embodiments, the identification of a number of labelled stress cell markers in a number of different segments, especially generally forming a ring or circle, or part of a ring or circle, or in adjacent segments, or segments within a few degrees of each other, is particularly indicative or predictive or macular disease, or of increased severity of macular disease. In some embodiments, the identification of at least 5, at least 10, at least 15, at least 20, at least 30 or at least 40 labelled cell stress marker positive cells in the image, in at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78,79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, or 360 of the 1° segments, optionally within about 1.00pm, 0.99pm, 0.98pm, 0.97pm, 0.96pm, 0.95pm, 0.94pm, 0.93pm, 0.92pm, 0.91pm, 0.90pm, 0.89pm, 0.88pm, 0.87pm, 0.86pm, 0.85pm, 0.84pm, 0.83pm, 0.82pm, 0.81pm, 0.80pm, 0.79pm, 0.78pm, 0.77pm, 0.76pm, 0.75pm, 0.74pm, 0.73pm, 0.72pm, 0.71pm, 0.70pm, 0.69pm, 0.68pm, 0.67pm, 0.66pm, 0.65pm, 0.64pm, 0.63pm, 0.62pm, 0.61pm, 0.60pm, 0.59pm, 0.58pm, 0.57pm, 0.56pm, 0.55pm, 0.54pm, 0.53pm, 0.52pm, 0.51pm, 0.50pm, 0.49pm, 0.48pm, 0.47pm, 0.46pm, 0.45pm, 0.44pm, 0.43pm, 0.42pm, 0.41pm, 0.40pm, 0.39pm, 0.38pm, 0.37pm, 0.36pm, 0.35pm, 0.34pm, 0.33pm, 0.32pm, 0.31pm, 0.30pm, 0.29pm, 0.28pm, 0.27pm, 0.26pm, 0.25pm, 0.24pm, 0.23pm, 0.22pm, 0.21pm, 0.20pm, 0.19pm, 0.18pm, 0.17pm, 0.16pm, 0.15pm, 0.14pm, 0.13pm, 0.12pm, 0.11pm, 0.10pm, 0.09pm, 0.08pm, 0.07 pm, 0.06pm, 0.05pm, 0.04pm, 0.03pm, 0.02pm, 0.01pm of the macula and particularly the fovea is indicative of having, or developing a disease of the macula, and / or of having an increased severity of disease.

[0072] Accordingly, the method may comprise the step of identifying of at least 5, at least 10, at least 15, at least 20, at least 30 or at least 40 labelled cell stress marker positive cells in the image, in at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75,76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, or 360 of the 1° segments, optionally within, at about or up to or at least 0.01pm, 0.02pm, 0.03pm, 0.04pm, 0.05pm, 0.06pm, 0.07pm, 0.08pm, 0.09pm, 0.10pm, 0.11pm, 0.12pm, 0.13pm, 0.14pm, 0.15pm, 0.16pm, 0.17pm, 0.18pm, 0.19pm, 0.20pm, 0.21pm, 0.22pm, 0.23pm, 0.24pm, 0.25pm, 0.26pm, 0.27pm, 0.28pm, 0.29pm, 0.30pm, 0.31pm, 0.32pm, 0.33pm, 0.34pm, 0.35pm, 0.36pm, 0.37pm, 0.38pm, 0.39pm, 0.40pm, 0.41pm, 0.42pm, 0.43pm, 0.44pm, 0.45pm, 0.46pm, 0.47pm, 0.48pm, 0.49pm, 0.50pm, 0.51pm, 0.52pm, 0.53pm, 0.54pm, 0.55pm, 0.56pm, 0.57pm, 0.58pm, 0.59pm, 0.60pm, 0.61pm, 0.62pm, 0.63pm, 0.64pm, 0.65pm, 0.66pm, 0.67pm, 0.68pm, 0.69pm, 0.70pm, 0.71pm, 0.72pm, 0.73pm, 0.74pm, 0.75pm, 0.76pm, 0.77pm, 0.78pm, 0.79pm, 0.80pm, 0.81pm, 0.82pm, 0.83pm, 0.84pm, 0.85pm, 0.86pm, 0.87pm, 0.88pm, 0.89pm, 0.90pm, 0.91pm, 0.92pm, 0.93pm, 0.94pm, 0.95pm, 0.96pm, 0.97pm, 0.98pm, 0.99pm, 1.00pm from the macula and particularly the fovea.

[0073] The method may comprise the step of identifying of at least 5, at least 10, at least 15, at least 20, at least 30 or at least 40 labelled cell stress marker positive cells in the image, in at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102,103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, or 360 adjacent segments or segments within at least or exactly or less than 1, 2, 3, 4, or 5° of the nearest segment containing at least 5, at least 10, at least 15, at least 20, at least 30 or at least 40 labelled cell stress marker positive cells, optionally within, at about or up to or at least 0.01pm, 0.02pm, 0.03pm, 0.04pm, 0.05pm, 0.06pm, 0.07pm, 0.08pm, 0.09pm, 0.10pm, 0.11pm, 0.12pm, 0.13pm, 0.14pm, 0.15pm, 0.16pm, 0.17pm, 0.18pm, 0.19pm, 0.20pm, 0.21pm, 0.22pm, 0.23pm, 0.24pm, 0.25pm, 0.26pm, 0.27pm, 0.28pm, 0.29pm, 0.30pm, 0.31pm, 0.32pm, 0.33pm, 0.34pm, 0.35pm, 0.36pm, 0.37pm, 0.38pm, 0.39pm, 0.40pm, 0.41pm, 0.42pm, 0.43pm, 0.44pm, 0.45pm, 0.46pm, 0.47pm, 0.48pm, 0.49pm, 0.50pm, 0.51pm, 0.52pm, 0.53pm, 0.54pm, 0.55pm, 0.56pm, 0.57pm, 0.58pm, 0.59pm, 0.60pm, 0.61pm, 0.62pm, 0.63pm, 0.64pm, 0.65pm, 0.66pm, 0.67pm, 0.68pm, 0.69pm, 0.70pm, 0.71pm, 0.72pm, 0.73pm, 0.74pm, 0.75pm, 0.76pm, 0.77pm, 0.78pm, 0.79pm, 0.80pm, 0.81pm, 0.82pm, 0.83pm, 0.84pm, 0.85pm, 0.86pm, 0.87pm, 0.88pm, 0.89pm, 0.90pm, 0.91pm, 0.92pm, 0.93pm, 0.94pm, 0.95pm, 0.96pm, 0.97pm, 0.98pm, 0.99pm, 1.00pm from the macula and particularly the fovea.

[0074] Where the method comprises the step of identifying at least 10, at least 15, at least 20, at least 30 or at least 40 labelled cell stress marker positive cells in particular segments, the segments in which such cells are identified may be indicative of the direction of growth of atrophy. In some embodiments, the step of providing or generating an image is repeated to obtain a second, third, fourth, fifth or more additional images. The steps of identifying one or morestressed cells image and assessing the arrangement of the one or more stressed cells using angular plot analysis may be repeated on those additional images. The arrangement of stressed cells may be compared to one or more preceding arrangements of stressed cells in that subject. Repetition may be every month, every two months, every six months, annually or biennial (once every two years). The method may comprise comparing the arrangement of one or more stressed cells in one, two, three, four or more preceding images. Comparing images of the same area of the subject over time may be used to monitor the progression of disease, for example if more stressed cells are found within a certain distance of an area of interest, it may be concluded that a disease is progressing. Alternatively, in embodiments where an appropriate treatment has been administered, comparing images of the same area of the subject over time may be used to monitor the efficacy of treatment administered. For example, after generating a first image, the subject may be administered an appropriate treatment. Any subsequent images obtained can be used to monitor the efficacy of said treatment.

[0075] In some embodiments, the method may be carried out on a subject on which another method has already been carried out to try to diagnose or predict the likelihood of the subject developing a particular disease. The present method can therefore be used as a "second opinion" to test and / or improve the accuracy of the another (first) method, and to ensure that any false negatives from the first method are identified.

[0076] According to a second aspect of the invention, there is provided a labelled cell stress marker for identifying, predicting, staging or prognosticating a disease of the macula in a subject, wherein the disease is identified, predicted, staged or prognosticated using the method of the first aspect of the invention.

[0077] In particular, the invention may be as defined in one or more of the following clauses, optionally in combination with any of the other features mentioned herein.

[0078] Clauses

[0079] 1. A method of identifying, predicting, staging or prognosticating a disease of the macula in a subject, the method comprising the steps of:

[0080] providing a first image of the retina of a subject to whom a labelled cell stress marker has been administered;

[0081] identifying one or more labelled cell stress marker positive cells in that image; andassessing the arrangement of the one or more labelled cell stress marker positive cells using angular plot analysis.

[0082] 2. The method of clause 1, wherein the stressed cells are cells that undergo stress in macular diseases.

[0083] 3. The method of clause 1 or clause 2, wherein the stressed cells are selected from RPE cells and photoreceptor cells, and are particularly photoreceptor cells.

[0084] 4. The method of any preceding clause, wherein the disease of the macula is selected from Age-related Macular Degeneration (AMD), Stargardt Disease, Best Disease (Best Vitelliform Macular Dystrophy), Macular Telangiectasia Type 2 (MacTel 2), Cone-Rod Dystrophy, Pattern Dystrophies, Geographic Atrophy (GA), Chronic Central Serous Chorioretinopathy, Choroideremia, Gyrate Atrophy, Toxin based diseases such as Thioridazine Toxicity and Hydroxychloroquine Toxicity, and Advanced Retinitis Pigmentosa.

[0085] 5. The method of clause 4, wherein the disease of the macula is AMD or GA.

[0086] 6. The method of any preceding clause, wherein the cell stress marker is an annexin or a fragment or variant thereof.

[0087] 7. The method of clause 6, wherein the annexin is selected from annexin 5, 11, 2 and 6.

[0088] 8. The method of any preceding clause, wherein the label of the cell stress marker is a visible label.

[0089] 9. The method of any preceding clause, wherein the label of the cell stress marker is fluorescent.

[0090] 10. The method of claim 9, wherein the label of the cell stress marker has an emission wavelength of about 400nm to about lOOOnm.

[0091] 11. The method of any preceding clause, wherein the label of the cell stress marker is one or more of sodium fluorescein, indocyanine green (ICG), curcumin, IRDye700, Dy- 776 (which may otherwise be referred to as D-776), Dy- 488 and Dy-781.

[0092] 12. The method of any preceding clause, wherein the disease is identified, predicted, staged or prognosticated, based on the number and / or position of stressed cells. 13. The method of any preceding clause, further comprising the step of step of identifying directional data about the one or more stressed cells identified, and relating that to progression of the disease of the macula.

[0093] 14. The method of any preceding clause, further comprising the step of dividing the whole or part of the image of the retina into a plurality of segments.The method of any preceding clause, wherein the step of identifying one or more labelled cell stress marker positive cells in that image comprises identifying the one or more stressed cells in each segment.

[0094] The method of any preceding clause, wherein the segments are angular segments arranged around a particular analysis point.

[0095] The method of any preceding clause, wherein the analysis point is a lesion, or a particular point on the retina, such as part of the macula, such as the fovea, especially the fovea centralis.

[0096] The method of any preceding clause, further comprising the step of totalling the number of stressed cells in each segment.

[0097] The method of clause 18, further comprising the step of plotting the total number of stressed cells in each segment in an angular plot.

[0098] The method of clause 19, further comprising the step of analysing the number and arrangement of segments in which stressed cells are found, and relating the number and arrangement to the presence, stage or prognosis of a disease of the macula.

[0099] The method of any preceding clause, wherein the identification of at least 5 cell stress marker positive cells in the image is indicative or predictive of the subject having or developing a disease of the macula, or indicative of the severity of that disease.

[0100] The method of any of clauses 16 to 21, wherein the identification of at least 5 cell stress marker positive cells in the image, within about 0.01pm of the macula is predictive of the subject having or developing a disease of the macula and / or of the severity of that disease.

[0101] The method of any of clauses 16 to 22, wherein the identification of at least 5 cell stress marker positive cells in the image, in at least 2 of the 1° segments is having, or developing a disease of the macula, and / or of having an increased severity of disease. The method of any preceding clause, wherein the location of stressed cells identified in the image is indicative of the location or direction of growth of the disease of the macula.

[0102] The method of any preceding clause, further comprising the steps of:

[0103] providing or generating second, third, fourth, fifth or further additional images; identifying one or more stressed cells in said image(s);

[0104] assessing the arrangement of the one or more stressed cells using angular plot analysis; andcomparing the arrangement of the one or more stressed cells to one or more preceding arrangements of stressed cells in that subject.

[0105] 26. The method of any preceding clause, further comprising the step of generating an image from the subject using an imaging device.

[0106] 27. The method of any preceding clause, further comprising the step of administering a labelled cell stress marker to the subject.

[0107] 28. The method of any preceding clause, further comprising the step administering an appropriate treatment for the disease, stage of disease, severity of disease or predicted disease identified.

[0108] 29. A labelled cell stress marker for identifying, predicting, staging or prognosticating a disease of the macula in a subject, wherein the disease is identified, predicted, staged or prognosticated using the method of any preceding clause.

[0109] 30. The use of a labelled cell stress marker in the preparation of an agent for use in identifying, predicting, staging or prognosticating a disease of the macula in a subject, wherein the disease is identified, predicted, staged or prognosticated using the method of any of clauses 1 to 28.

[0110] 31. A medicament for the treatment of a disease of the macula, wherein the disease is identified, predicted, staged or prognosticated using the method of any of clauses 1 to 28.

[0111] 32. A computer-readable medium having computer-executable instructions stored thereon that, when executed by a computer, cause the computer to carry out the method of any of clauses 1 to 25.

[0112] Throughout the description and claims of this specification, the words "comprise" and "contain" and variations of the words, for example "comprising" and "comprises", mean "including but not limited to", and do not exclude other components, integers or steps.

[0113] Moreover, the singular encompasses the plural unless the context otherwise requires; in particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.

[0114] Preferred features of each aspect of the invention may be as described in connection with any of the other aspects. Within the scope of this application, it is expressly intended that the various aspects, embodiments, examples and alternatives set out in the preceding paragraphs, in the claims and / or in the following description and drawings, and in particular the individual features thereof, may be taken independently or in any combination. That is, allembodiments and / or features of any embodiment can be combined in any way and / or combination, unless such features are incompatible.

[0115] The invention will now be described in detail, with reference to the drawings.

[0116] DESCRIPTION OF THE DRAWINGS

[0117] Figure 1 shows a rat eyes having atrophy, with a ring of DARC spots around the site of the atrophy.

[0118] Figures 2 to 4 show simulated images of analysed eyes.

[0119] Figure 5 shows the workflow of generating an angular plot from DARC spots, (a) shows baseline atrophy in NIR image. The process begins with the annotation of DARC spots in NIRAF image (b), which is followed by a transformation into a DARC density heatmap (c) to visualize spatial distribution. The density map is then segmented into 1 -degree angular slices centred at the centre of atrophy (d), with each angle evaluated for its total DARC density score (e). These scores are plotted as individual bars at their respective angles (f) and finally combined into a single angular plot (g) to depict the directional predictive growth of DARC. Figure 6 shows the workflow of generating an angular plot from EZ Loss, (a) shows baseline atrophy in NIR image. A 2D U-Net is used to analyse EZ loss in volumetric OCT slices and transformed into a 2D projection and overlay ed with baseline image (b). The overlay is then segmented into 1 -degree angular slices centred at the centre of atrophy (c), with each angle evaluated by calculating the mean distance from atrophy centre to EZ edge (e). These scores are plotted as individual bars at their respective angles (e) and finally combined into a single angular plot (f) to depict the directional predictive growth of EZ.

[0120] Figure 7 shows directional angular analysis comparing MA growth rate (red, a-d) with baseline predictors : a) DARC density (green, Pearson correlation coefficient 0.054); b) mean EZ loss (yellow, Pearson correlation coefficient -0.565), c) EZ-RPE difference (purple, Pearson correlation coefficient -0.565), and d) HRF density (orange, Pearson correlation coefficient -0.066). The DARC signal demonstrated a significantly greater correlation to MA growth compared to baseline EZ loss (p<0.0001) and baseline EZ-RPE difference (p<0.0001), but no statistical significance compared to HRF (p=0.054). In this case, baseline EZ and EZ-RPE predicted growth in the opposite direction to the actual MA expansion, while HRF density showed minimal directional association with MA growth. Note Cyan “+” denotes the foveal centre.Figure 8 is a line graph showing the normalised squared rank difference between MA growth rate and each baseline metric across 1 -degree angular sectors spanning the full 360° circle. DARC is shown in green (Pearson correlation coefficient 0.054) and compared to other metrics a) EZ loss (yellow, Pearson correlation coefficient -0.565), b) EZ-RPE loss (purple, Pearson correlation coefficient -0.565), and c) HRF density (orange, Pearson correlation coefficient -0.066)). Panel d shows all four metrics plotted together relative to MA growth rate. Lower normalised squared rank differences indicate closer directional agreement with observed MA growth.

[0121] Figure 9 shows comparison of Pearson Correlation with MA growth between DARC density and EZ loss, DARC density and EZ-RPE, and DARC density and HRF density based on paired comparisons at the eye level (n=7). Paired violin plots show that DARC density has the strongest predictive ability for future directional MA growth across the seven cases. Green markers indicate eyes without MA at baseline; orange markers indicate the representative case shown in the main paper. HRF density was evaluated from the time of atrophy onset in eyes without baseline atrophy.

[0122] Figure 10 shows a comparison of the difference between the best performer and other metrics based on paired comparisons at the eye level (n=7). Paired violin plots showed that DARC has the smallest difference from the best performer overall compared to EZ loss, EZ-RPE difference and HRF. HRF was evaluated from the onset of atrophy in eyes without baseline atrophy, yet DARC still demonstrated superior predictive ability for future directional MA growth across the full circular analysis.

[0123] Figure 11 shows hypothetical cellular zones of activity: an innermost zone of MA corresponding to RPE death; a surrounding zone of EZ attenuation corresponding to photoreceptor death; and finally, an outer zone of DARC corresponding to stressed and apoptotic photoreceptors. This may explain why the DARC density heat map appears distal to the atrophic region, and why DARC can predict future growth of atrophy.

[0124] EXAMPLES

[0125] Example 1

[0126] The inventors assessed a series of rat eyes, each having atrophy around the optic disc, shown in figure 1. The eyes were evaluated using DARC, labelling apoptosing cells with annexin 5 labelled with Dye776. The inventors noted the prevalence of DARC spots around the edge of the atrophy.Example 2

[0127] Summary

[0128] Eyes identified with MA were evaluated for MA growth, EZ and DARC assessment. MA growth was determined by analyzing sequential follow-up retinal scans (both reflective and OCT) and based on the area between the atrophy’s edge at the final follow-up and either the preexisting edge at baseline or the earliest detected appearance of MA. The baseline EZ measurement was calculated as the mean distance from the outer edge of EZ loss to the center of the MA lesion. Similarly, the DARC signal was quantified from baseline DARC density maps. Angular plots of DARC, EZ and MA growth for each eye were then generated, with the quantity of DARC or EZ compared to MA growth in 1-degree sectors of a full circle (360 degrees) centred on the MA lesion. Spearman’s rank correlation coefficient was used to determine the strength of correlation between the directional association between MA growth and each of DARC density and mean EZ loss.

[0129] Angular visualisation maps of MA growth, baseline DARC density and EZ loss were constructed for 7 eyes with mean follow-up of 48.4 months (range: 16.3 - 57.7 months). DARC activity was visualized distally relative to future growth areas compared to EZ loss which was seen adjacent to existing MA. The angular correlation between directional DARC signal and the square root (sqrt) MA growth rate was significantly stronger than EZ loss (p = 0.033). Angular plot analysis showed DARC a greater ability to predict future directional growth of MA.

[0130] Angular plot analysis presents an intuitive, comprehensive and accurate method to evaluate the role of DARC and EZ in predicting the future direction of MA growth. The role of DARC appears to show a stronger and more consistent ability to predict future directional growth of atrophy than EZ. This has greatest implications with identifying patients at greatest risk of vision loss with sub-foveal and extra-foveal MA and their management.

[0131] Methods and Results

[0132] Data collection

[0133] 4 eyes were identified with DARC counts and extrafoveal MA at baseline (17), and 3 eyes without MA at baseline but who developed atrophy during follow-up. Simulated images of the eyes are provided in figures 2 to 4.

[0134] Annotation of growth of MANIR images (768*768 pixels) were annotated manually by two experienced ophthalmologists using ImageJ (open-source software for image processing and analysis in Java). If there was a disagreement, the two ophthalmologists reviewed together and confirmed the final annotation. MA was defined as sharply demarcated and hyperreflective areas in NIR images (based on the consensus 2018 report), which were annotated using a computer mouse with a unique colour, followed by a strict and corresponding comparison to volumetric OCT scans to ensure accurate delineation of atrophy and exclusion of fibrosis. MA growth was calculated as the difference between MA areas at follow-up and baseline, with overlays of the growth generated on the baseline NIR image.

[0135] Development of angular plot analysis

[0136] The predictive abilities of DARC, EZ loss, EZ-RPE difference and HRF in modelling disease progression using angular plots was compared. Python scripts were widely used during the whole process to avoid variability and demonstrate reproducibility.

[0137] Calculation of EZ Loss

[0138] Photoreceptor integrity and its relationship with MA progression was assessed by first analysing EZ loss (segmentation of RPE loss) using our previously described 2D U-Net model on volumetric OCT slides (27). The loss of EZ at baseline was delineated in each volumetric OCT slice (49*512*496 pixels) and after automated detection, each volume containing predictions of EZ loss was imported by image sequence to ImageJ, and a 2D projection to construct an en-face image. This en-face image was overlay ed on to the NIR image using resizing and registration metrics obtained from the Spectralis metadata including scaling and distance between each B-scan. Finally, the MA baseline area was subtracted from the baseline area of EZ loss, giving a clear visual representation of the directional prediction compared to the actual atrophy growth. Interestingly, most EZ loss inferiorly in this case was associated with subretinal fluid that disrupted EZ.

[0139] Creation of DARC density heatmap

[0140] Images with DARC were recorded at 120 min after ANX776 administration using ICGA settings in confocal scanning laser ophthalmoscope (cSLO), as previously described. The fluorescent DARC spots observed in the images were identified as ANX776-positive labelled cells, appearing as hyperfluorescent spots on the retina, with diameters ranging from 12 to 16 pm. Baseline NIRAF and DARC images were reviewed first by one ophthalmologist who annotated DARC spots using ImageJ (open-source software for image processing andanalysis in Java), as previously described. After that, the results were manually checked by a second ophthalmologist. In the case of a disagreement, two ophthalmologists reviewed together and made final decisions of DARC spots.

[0141] Next, DARC spot locations were aligned and mapped to the baseline NIRAF subtraction image to create a density map as previously described generated using Python scripts that convolved the DARC points with a Gaussian kernel of a standard deviation of 40 pixels. A threshold was applied to the resulting density map, to convert all near-zero pixels to zero and subsequently overlayed on the NIRAF image to allow visualisation of the spatial distribution of DARC compared to MA.

[0142] Calculation of HRF

[0143] In order to calculate local HRF correlation with MA growth, the inventors followed the method proposed in Schmidt-Erfurth U, Bogunovic H, Grechenig C, et al. Role of deep learning-quantified hyperreflective foci for the prediction of geographic atrophy progression. American journal of ophthalmology 2020; 216: 257-270, pertaining to local HRF concentration, briefly described here. HRF was manually annotated by two experienced ophthalmologists through volumetric baseline OCT slices (49*512*496 pixels) using ImageJ. If there was a disagreement, the two ophthalmologists reviewed together and confirmed the final annotation. HRF was defined as small, dot-shaped lesions with equal or higher reflectivity than RPE in OCT slices. Only HRFs within a radius 800um from the MA atrophy border were chosen, as previously described. After manual annotation of HRF, each OCT volume containing HRF was automatically projected to generate a 2D en-face image using Python scripts. This en-face image was then overlaid on to the NIR image, similar to methodology described previously for EZ loss (Figure 4).

[0144] Creation of DARC angular plots

[0145] The DARC density representation was then transformed into directional data, by dividing the DARC density heatmap into 1-degree sectors of a full circle (360 degrees), positioned around the centre of the MA lesion. The total quantity of DARC signal for each 1-degree sector was calculated as the sum of all density values in that sector (Figure 5e). This total density value for each 1-degree sector was the plotted on a circular bar chart, which we refer to as an angular plot (Figure 51). The individual bars were finally combined to create a single angular plot which formed the basis for analysing the capability of predicting directional growth (Figure 5g).Creation of EZ angular plot

[0146] In order to make comparisons about the predictive ability of DARC, angular plots for EZ were created using a similar process. The 2D projection of EZ 27 was split into 360 1-degree sectors centred around the centre of atrophy (Figure 6c). The score for each 1-degree sector (mean EZ loss, (pm)) was defined as the mean distance from the outer edge of EZ loss to the centre of MA within that 1-degree sector (Figure 6d). These scores were combined and plotted as individual bars on a new angular plot describing the directional predicted growth of EZ (Figure 61).

[0147] Creation of EZ-RPE difference angular plot

[0148] Creation of the angular plots for EZ-RPE followed a very similar workflow to EZ. Baseline RPE loss was defined as the distance from the baseline margin of MA to the MA centre. Where no MA was detected at baseline, baseline RPE loss was set to 0, making the EZ-RPE difference equivalent to the EZ plot in those cases.

[0149] Creation of HRF angular plot

[0150] As described previously, calculation of local HRF followed the methodology proposed by Schmidt-Erfurth, et al. Briefly, coordinates of each boundary pixel of the first detection of MA were extracted. For each boundary location, a circle of radius 800um was defined, within which a density value of HRF was calculated. The HRF density was then transformed into 1-degree angular buckets centred around the atrophy centre by averaging scores across all border pixel that appeared in that given angle. Angular plots were then generated by following the same final steps of the DARC / EZ workflows.

[0151] The number of angles with missing HRF data varied depending on the size of the onset of MA relative to the resolution of the image. As missing angles are caused by sampling resolution and not a biological absence, for visualisation of angular plots, linear interpolation was applied to the local HRF angular density to obtain a continuous curve. This interpolation was used purely for visualisation purposes and was not applied to any statistical analysis. Comparison of DARC, EZ, EZ-RPE difference and HRF angular plots against MA Growth.

[0152] For comparisons against MA growth, we used two different methods. Firstly, to compare HRF, we again follow the methodology proposed by Schmidt-Erfurth et al. The MA growth per boundary pixel of first detected MA was measured by defining the normal vector between the centre of atrophy and each boundary pixel. The distance between the boundary of initial onset and the corresponding boundary position at follow up was then calculated along thisnormal. 1 -degree angular buckets were then generated by averaging scores of contained boundary pixels. As with HRF, missing angles are interpolated and plotted on the HRF angular plot.

[0153] For comparisons against DARC, EZ and EZ - RPE, the area between the edge of atrophy, atrophy boundary at final available follow-up and the edge of preexisting or earliest appearance of MA in each 1 -degree sector was used to calculate the area of MA growth. The sqrt growth rate of MA per year, as previously used in other studies, for each 1 -degree sector was then calculated using the following equations:

[0154] z / jx _AfinalW

[0155] Kgrowth\° )A

[0156]

[0157] ^baseline J

[0158] Where RgrOwth (0) is the growth ratio of MA for the 0-th sector of the circle, Afinai(f ) is the area of MA growth in the 0-th sector at final follow-up and AbaseUne(ff) is the area of MA in the 0-th sector at baseline or the timepoint of onset.

[0159] , , _ jRgrowthSfi')

[0160] ‘ growth I” J y

[0161]

[0162] 1 follow-up

[0163] Where rgrowth(0) is the sqrt growth rate of MA per year for the 0-th sector and

[0164] 7

[0165]

[0166] / oHow-up(0) is the total follow-up in years from the onset of MA. The sqrt growth rate for each 1 -degree sector is then normalized and plotted on each of the DARC, EZ and EZ-RPE difference angular plots.

[0167] Statistical analysis

[0168] Spearman’s rank correlation coefficient was used to assess the directional association between MA growth rate and each of the four predictive angular plot methods at the eye level: DARC density, mean EZ loss, EZ-RPE difference and HRF density, using python (v 3.12) and SciPy stats (vl.14.1). The ranks were assigned to each 1-degree sector by ordering the growth rate, DARC, EZ, EZ-RPE and HRF from highest to lowest at the eye level.

[0169] The correlation coefficient was calculated using Pearson’s correlation formula on ranked data rather than the standard Spearman’s rank formula. This approach was necessary because the angular data contained tied ranks, and by definition, the Spearman’s rank formula is a special case of Pearson’s correlation applied to ranked data with no ties.

[0170] Steiger’s z test was applied to test the significance of difference between correlation coefficients of sqrt growth of MA with the DARC density, and differences betweencorrelation coefficients of sqrt growth of MA with EZ loss, EZ-RPE difference and HRF respectively.

[0171] For visualising angular-level agreement between predicted and observed MA growth, squared rank differences were calculated for each 1 -degree sector between MA growth rate and each predictor (DARC density, EZ loss, EZ-RPE difference, and HRF density). For a given sector, this value reflects how closely the predictor ranked that angular direction relative to the actual growth rate, with smaller squared differences indicating stronger directional alignment and larger values indicating greater directional discordance. These squared rank differences were normalised and plotted as angular maps to facilitate comparison across methods. This provides a more visual representation of the directional performance of each method compared to MA growth, as illustrated in Figure 8.

[0172] For a patient, the correlation coefficients were 0.054 for DARC, -0.565 for EZ loss, -0.565 for the EZ-RPE difference, and -0.066 for HRF. Relative to the other biomarkers, DARC exhibited the greatest directional concordance with atrophy expansion, being the only metric with a positive correlation, while EZ-based measures predicted growth in the opposite direction and HRF showed little directional alignment.

[0173] A paired t-test (GraphPad Prism version 10.2.3, GraphPad Software, San Diego, California, USA) was used to compare predictive abilities of DARC density and EZ loss to sqrt growth rate of MA across all 7 available cases. Figure 9 illustrates DARC density was consistently higher in predicting future atrophy compared to EZ loss, and that this was statistically significant (p =0.033; paired t-test).

[0174] Comparison of DARC, EZ, EZ-RPE difference and HRF angular plots against MA Growth in all 7 cases

[0175] Across the seven cases, DARC density demonstrated the strongest ability to predict future directional MA atrophy compared with EZ loss (Figure 9a, p = 0.0191), EZ-RPE difference (Figure 9b, / ? = 0.0267), and HRF density (Figure 9c, p = 0.0252), reaching statistical significance in paired, one-tailed parametric / -tests at the eye level (n=7) using per-eye correlation coefficients. To note, one-tailed testing is based on an a priori directional DARC hypothesis.

[0176] Notably, HRF density could not be quantified at baseline in three eyes (Figure 9, green & orange markers) due to the absence of baseline atrophy, limiting its applicability as a true baseline predictive biomarker. To enable a fair and conservative comparison, HRFmeasurements were therefore aligned to the time point of atrophy onset rather than baseline. Despite this adjustment, DARC density remained significantly superior, underscoring its robustness as an early predictor of future atrophy progression.

[0177] Furthermore, the performance of four metrics was ranked based on their correlation to MA growth rate. Differences between the top-ranked metric and all others were compared using paired / -tests. As shown in Figure 10, DARC density exhibited the smallest deviation from the best-performing metric, significantly outperforming EZ loss (p = 0.0191), EZ-RPE difference (p = 0.0267), and HRF density (p = 0.0252). Again, HRF density could not be assessed at baseline in three eyes (orange and green markers) lacking baseline atrophy and was instead evaluated at the time of atrophy onset. Even under this favourable analytical adjustment for HRF, DARC density consistently demonstrated the strongest predictive performance for long-term directional MA growth.

[0178] Discussion

[0179] This is the first time angular plot analysis, a novel analysis method, has been applied to MA. Using this tool, the inventors compared the ability of DARC, EZ loss, EZ-RPE difference and HRF in predicting the future direction of MA growth. Across the seven cases analysed, DARC density demonstrated the strongest and most consistent association with future directional MA expansion compared with the other biomarkers.

[0180] The use of angular plot analysis is a new application in OCT imaging for AMD, evaluating directional and comprehensive progression of atrophy. However, this special analysis has been widely and successfully used in the field of meteorology to forecast wind speed, direction and power density. The distinctive capability of plotting vectors in a circular arrangement represents both magnitude and spatial information, making it useful for applications to predict wind speed and direction.

[0181] Angular plot analysis also provides a unique perspective for patients with AMD, and opens a window to explore promising biomarkers for predicting future directions of atrophy growth and evaluate their effectiveness.

[0182] Although EZ is used as a surrogate endpoint of MA growth, its ability to predict direction of growth has not previously been analysed. Here, the inventors describe this novel angular analysis method to assess this aspect, and simultaneously compare it to DARC.EZ integrity is now recognized as an imaging biomarker for MA. It is currently utilized in clinical drug development trials, demonstrating areas of overlap between baseline EZ loss and future atrophy. The inventors’ analysis supports these findings, which align with the natural progression of atrophy. Initially, photoreceptor death occurs, followed by RPE degeneration, corresponding with specific structural changes observed in OCT at each stage of atrophy. This relationship explains why the area of EZ loss surrounds the region of RPE degeneration, thereby predicting future atrophy expansion.

[0183] EZ-based loss by segmentation is evenly distributed around MA and thus, by itself, may not be suitable for predicting the direction of growth. In addition, EZ loss may be influenced by the persistence of subretinal fluid in wet AMD, therefore, EZ loss does not accurately reflect the true progression of MA. There is increasing recognition that identifying patients with intermediate AMD who are at high risk of vision loss is an unaddressed need. In AMD, as soon as the fovea is affected, visual acuity deteriorates rapidly, making it essential to prevent MA from involving the fovea to preserve vision. Our results indicate that DARC can help identify eyes at risk of vision loss, potentially enabling earlier intervention and improved outcomes. This approach may reduce MA expansion to the fovea and help preserve vision. Compared to EZ and EZ-RPE, baseline DARC density can indicate the direction of MA expansion, which is crucial for patients with extrafoveal lesions.

[0184] Baseline DARC density heatmap visualization demonstrates that DARC activity occurs beyond the distal edge of MA. In comparison, the EZ area of attenuation is directly adjacent to the area of MA. Based on angular analysis of 7 cases, the inventors believe that the differences in patterns of MA, EZ, and DARC activity reflect the anatomical cellular activity that can be divided into 3 zones as illustrated in Figure 11: an innermost zone of MA corresponding to RPE death; a surrounding zone of EZ attenuation corresponding to photoreceptor death; and finally, an outer zone of DARC corresponding to stressed and apoptotic photoreceptors. The inventors believe it is the cellular activity identified by DARC that enables it to predict the future growth of MA compared to EZ.

[0185] HRF have recently been shown to correlate with MA progression. In the angular plot analysis, HRF density demonstrated a meaningful association with the future direction of MA growth and in two individual cases (0.803 vs. 0.738 (case without baseline atrophy); 0.739 vs. 0.713 (case with baseline atrophy)), showed performance marginally exceeding that of DARC. These findings are consistent with prior studies suggesting that HRF may identify regions of impending atrophy.However, several key differences distinguish HRF from DARC as predictive biomarkers. First, HRF density could not be quantified at baseline in three eyes without established atrophy, as HRF typically emerge only after structural retinal disruption has occurred. This limits HRF’s applicability as a true early predictive biomarker. To enable comparison in these cases, HRF measurements were therefore aligned to the time point of atrophy onset rather than baseline - an approach that favours HRF performance and represents a conservative analytical choice. Despite this adjustment, DARC density retained superior overall predictive ability across cases. Second, HRF are biologically heterogeneous and may represent multiple pathological processes, including activated microglia, migrating RPE cells, lipid-laden macrophages, or inflammatory components associated with neovascularisation. As a result, HRF lack specificity for dry AMD and MA progression alone. In contrast, DARC directly labels stressed and apoptotic retinal cells, providing a mechanistically distinct and more proximal signal of impending tissue loss. This biological specificity likely underpins DARC’s ability to predict not only where atrophy will expand, but also before overt structural damage becomes apparent on OCT. Third, while HRF tended to cluster closer to existing areas of atrophy, DARC signal was frequently detected beyond the distal margin of MA, consistent with an earlier stage of cellular stress. This spatial distinction was evident in the angular analysis, where DARC showed greater consistency in predicting directional growth over long-term follow-up. Although HRF performed strongly in several cases, its predictive capacity appeared more dependent on established disease, whereas DARC provided prognostic information at an earlier disease stage.

[0186] Taken together, our findings suggest that HRF and DARC reflect different phases of disease biology. HRF may serve as a valuable marker of active or advanced disease, whereas DARC appears to identify earlier cellular stress that precedes irreversible structural loss. This distinction is clinically important, as early identification of eyes at risk of directional MA progression, offers a greater opportunity for timely intervention.

[0187] Drusen dynamics are widely recognised as hallmarks of early AMD and are associated with progression to MA. However, drusen are not uniquely specific to AMD, and not all drusen progress to MA. Moreover, drusen regression is influenced by its initial volume - larger drusen volumes tend to regress more. In addition, drusen regression is more common in dry AMD rather than wet AMD. Given these limitations, drusen metrics were not included as comparative biomarkers in this study.Conclusion

[0188] In conclusion, angular plot analysis offers an intuitive, comprehensive, and precise approach for assessing the roles of DARC, EZ loss, EZ-RPE difference and HRF in predicting the future direction of MA growth. While HRF remains a strong biomarker of MA progression, its later emergence and limited baseline availability contrast with DARC’s ability to detect early cellular stress and consistently predict the directional expansion of atrophy.

[0189] Our exploratory findings here, suggest that DARC signals have the potential to forecast both the onset of atrophy and the long-term trajectory of its expansion. Notably, this study represents the first report demonstrating DARC’s ability to predict the directional progression of MA in AMD patients.

[0190] Overall, DARC demonstrated a more robust and reliable performance in predicting the future directional growth of atrophy compared to EZ loss, EZ-RPE difference and HRF in this exploratory study. This capability is particularly important for identifying patients at the highest risk of vision loss, especially those with sub-foveal and extra-foveal MA. A more precise understanding of atrophy progression enabled by DARC may support early intervention strategies and inform more effective, targeted patient management.

[0191] References

[0192] 1. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014; 2: el06-116. 2014 / 08 / 12. DOI: 10.1016 / s2214-109x(13)70145-l.

[0193] 2. Ricci F, Bandello F, Navarra P, et al. Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. IntJMol Sci 2020; 21 2020 / 11 / 07. DOI: 10.3390 / ijms21218242.

[0194] 3. Fleckenstein M, Mitchell P, Freund KB, et al. The progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology 2018; 125: 369-390.

[0195] 4. Sadda SR, Tuomi LL, Ding B, et al. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology 2018; 125: 878-886.

[0196] 2018 / 02 / 27. DOI: 10.1016 / j.ophtha.2017.12.026.

[0197] 5. Abdelfattah NS, Al-Sheikh M, Pitetta S, et al. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab:Findings from the TREX- AMD Trial. Ophthalmology 2017; 124: 215-223. 2016 / 11 / 20. DOI: 10.1016 / j.ophtha.2016.10.002.

[0198] 6. Steinle NC, Pearce I, Mones J, et al. Impact of baseline characteristics on geographic atrophy progression in the FILLY trial evaluating the complement C3 inhibitor pegcetacoplan. American journal of ophthalmology 2021; 227: 116-124.

[0199] 7. Goldberg R, Heier JS, Wykoff CC, et al. Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12-month results from the phase 3 OAKS and DERBY studies. Investigative Ophthalmology & Visual Science 2022; 63: 1500-1500.

[0200] 8. Jaffe GJ, Westby K, Csaky KG, et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2 / 3 trial.

[0201] Ophthalmology 2021; 128: 576-586.

[0202] 9. Kalra G, Cetin H, Whitney J, et al. Automated identification and segmentation of Ellipsoid Zone At-Risk using deep learning on SD-OCT for predicting progression in dry AMD. Diagnostics 2023; 13: 1178.

[0203] 10. Litts KM, Zhang Y, Freund KB and Curcio CA. Optical coherence tomography and histology of age-related macular degeneration support mitochondria as reflectivity sources. Retina 2018; 38: 445-461.

[0204] 11. Lee KE, Heitkotter H and Carroll J. Challenges associated with ellipsoid zone intensity measurements using optical coherence tomography. Translational vision science & technology 2021; 10: 27-27.

[0205] 12. Pfau M, von der Emde L, de Sistemes L, et al. Progression of photoreceptor degeneration in geographic atrophy secondary to age-related macular degeneration. JAMA ophthalmology 2020; 138: 1026-1034.

[0206] 13. Reiter GS, Told R, Schranz M, et al. Subretinal drusenoid deposits and photoreceptor loss detecting global and local progression of geographic atrophy by SD-OCT imaging. Investigative Ophthalmology & Visual Science 2020; 61: 11-11.

[0207] 14. Abraham JR, Jaffe GJ, Kaiser PK, et al. Impact of baseline quantitative OCT features on response to risuteganib for the treatment of dry age-related macular degeneration: The importance of outer retinal integrity. Ophthalmology Retina 2022; 6: 1019-1027.15. Toth CA, Tai V, Pistilli M, et al. Distribution of OCT features within areas of macular atrophy or scar after 2 years of anti-VEGF treatment for neovascular AMD in CATT.

[0208] Ophthalmology Retina 2019; 3: 316-325.

[0209] 16. Mai J, Riedl S, Reiter GS, et al. Comparison of Fundus Autofluorescence Versus Optical Coherence Tomography-based Evaluation of the Therapeutic Response to Pegcetacoplan in Geographic Atrophy. American Journal of Ophthalmology 2022; 244: 175- 182.

[0210] 17. Mai J, Reiter GS, Riedl S, et al. Dynamics of the EZ / RPE Loss Ratio on OCT Over Time During Geographic Atrophy Progression and Treatment With Pegcetacoplan.

[0211] Investigative Ophthalmology & Visual Science 2025; 66: 48-48.

[0212] 18. Schmidt-Erfurth U, Mai J, Reiter GS, et al. Disease activity and therapeutic response to pegcetacoplan for geographic atrophy identified by deep learning-based analysis of OCT. Ophthalmology 2025; 132: 181-193.

[0213] 19. Nassisi M, Fan W, Shi Y, et al. Quantity of intraretinal hyperreflective foci in patients with intermediate age-related macular degeneration correlates with 1-year progression. Investigative ophthalmology & visual science 2018; 59: 3431-3439.

[0214] 20. Sleiman K, Veerappan M, Winter KP, et al. Optical coherence tomography predictors of risk for progression to non-neovascular atrophic age-related macular degeneration.

[0215] Ophthalmology 2 f 124: 1764-1777.

[0216] 21. Schlegl T, Bogunovic H, Klimscha S, et al. Fully automated segmentation of hyperreflective foci in optical coherence tomography images. arXiv preprint

[0217] arXiv: 1805032782018.

[0218] 22. Curcio CA, Zanzottera EC, Ach T, et al. Activated retinal pigment epithelium, an optical coherence tomography biomarker for progression in age-related macular degeneration. Investigative ophthalmology & visual science 2017; 58: BIO211-BIO226. 23. Christenbury JG, Folgar FA, O'Connell RV, et al. Progression of intermediate age-related macular degeneration with proliferation and inner retinal migration of hyperreflective foci. Ophthalmology 2013; 120: 1038-1045.

[0219] 24. Schmidt-Erfurth U, Bogunovic H, Grechenig C, et al. Role of deep learning-quantified hyperreflective foci for the prediction of geographic atrophy progression.

[0220] American journal of ophthalmology 2020; 216: 257-270.25. Cordeiro MF, Hill D, Patel R, et al. Detecting retinal cell stress and apoptosis with DARC: Progression from lab to clinic. Progress in Retinal and Eye Research 2022; 86:

[0221] 100976.

[0222] 26. Corazza P, Maddison J, Bonetti P, et al. Predicting wet age-related macular degeneration (AMD) using DARC (detecting apoptosing retinal cells) Al (artificial intelligence) technology. Expert Rev Mol Diagn 2021; 21: 109-118. 2020 / 12 / 24. DOI:

[0223] 10.1080 / 14737159.2020.1865806.

[0224] 27. Coulibaly LM, Reiter GS, Fuchs P, et al. Progression dynamics of early versus later stage atrophic lesions in nonneovascular age-related macular degeneration using quantitative OCT biomarker segmentation. Ophthalmology Retina 2023; 7: 762-770.

[0225] 28. Corazza P, Maddison J, Bonetti P, et al. Predicting wet age-related macular degeneration (AMD) using DARC (detecting apoptosing retinal cells) Al (artificial intelligence) technology. Expert review of molecular diagnostics 2021; 21: 109-118.

[0226] 29. Sadda SR, Guymer R, Holz FG, et al. Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3.

[0227] Ophthalmology 2 1 ,' 125: 537-548.

[0228] 30. Yehoshua Z, Rosenfeld PJ, Gregori G, et al. Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography. Ophthalmology 2011; 118: 679-686.

[0229] 31. Nunes RP, Gregori G, Yehoshua Z, et al. Predicting the progression of geographic atrophy in age-related macular degeneration with SD-OCT en face imaging of the outer retina. Ophthalmic surgery, lasers and imaging retina 2013; 44: 344-359.

[0230] 32. Stetson PF, Yehoshua Z, Garcia Filho CAA, et al. OCT minimum intensity as a predictor of geographic atrophy enlargement. Investigative ophthalmology & visual science 2014; 55: 792-800.

[0231] 33. Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology 2014; 121: 693-701.

[0232] 34. Shmueli O, Yehuda R, Szeskin A, et al. Progression of cRORA (Complete RPE and Outer Retinal Atrophy) in Dry Age-Related Macular Degeneration Measured Using SD-OCT. Translational Vision Science & Technology 2022,' 11: 19-19.35. Wei W, Southern J, Zhu K, et al. Deep learning to detect macular atrophy in wet age-related macular degeneration using optical coherence tomography. Scientific Reports 2023; 13: 8296.

[0233] 36. Bizrah M, Dakin SC, Guo L, et al. A semi-automated technique for labeling and counting of apoptosing retinal cells. BMC bioinformatics 2014; 15: 1-12.

[0234] 37. Feuer WJ, Yehoshua Z, Gregori G, et al. Square root transformation of geographic atrophy area measurements to eliminate dependence of growth rates on baseline lesion measurements: a reanalysis of age-related eye disease study report no. 26. JAMA ophthalmology 2013; 131: 110-111.

[0235] 38. Myers JLW, Arnold D. Research Design and Statistical Analysis (2nd ed.). Lawrence Erlbaum. 2003.

[0236] 39. Ihno A. Lee KJP. Calculation for the test of the difference between two dependent correlations with one variable in common, http : / / qnantpsy . org. , (2013).

[0237] 40. Droppo JG and Napier BA. Wind direction bias in generating wind roses and conducting sector-based air dispersion modeling. Journal of the Air & Waste Management Association 2008; 58: 913-918.

[0238] 41. Jeon J and Taylor JW. Using conditional kernel density estimation for wind power density forecasting. Journal of the American Statistical Association 2012; 107: 66-79.

[0239] 42. Wang Z and Liu W. Wind energy potential assessment based on wind speed, its direction and power data. Scientific reports 2021; 11: 16879.

[0240] 43. Poddaeva O and Fedosova A. Extreme wind speeds analysis using extended wind rose based on statistic methods. Energy Reports 2022; 8: 1177-1184.

[0241] 44. Martins A, Sousa J and Carvalho A. Comparing wind generation spatial profiles: A circular data approach. Comparing wind generation spatial profiles: A circular data approach 2015.

[0242] 45. Yap TE, Davis BM, Bloom PA, et al. Glaucoma Rose Plot Analysis: Detecting Early Structural Progression Using Angular Histograms. Ophthalmology Glaucoma 2022; 5: 562-571.

[0243] 46. Schubert H. Structure and function of the neural retina. YanoffM, Duker JS Ophthalmology Philadelphia, Mosby 2009: 511-514.47. Schmidt-Erfurth U, Waldstein SM, Klimscha S, et al. Prediction of individual disease conversion in early AMD using artificial intelligence. Investigative ophthalmology & visual science 2018; 59: 3199-3208.

[0244] 48. Frizziero L, Midena G, Danieli L, et al. Hyperreflective Retinal Foci (HRF):

[0245] Definition and Role of an Invaluable OCT Sign. Journal of Clinical Medicine 2025; 14: 3021.

[0246] 49. Duic C, Pfau K, Keenan TD, et al. Hyperreflective foci in age-related macular degeneration are associated with disease severity and functional impairment. Ophthalmology Retina 2023; 7: 307-317.

[0247] 50. Abdelsalam A, Del Priore L and Zarbin MA. Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Survey of ophthalmology 1999; 44: 1-29.

[0248] 51. Damian I and Nicoara SD. SD-OCT biomarkers and the current status of artificial intelligence in predicting progression from intermediate to advanced AMD. Life 2022; 12: 454.

[0249] 52. Yehoshua Z, Wang F, Rosenfeld PJ, et al. Natural history of drusen morphology in age-related macular degeneration using spectral domain optical coherence tomography. O

[0250]

[0251] phthalmology 118: 2434-2441.

[0252] 53. Ly A, Yapp M, Nivison-Smith L, et al. Developing prognostic biomarkers in intermediate age-related macular degeneration: their clinical use in predicting progression. Clinical and Experimental Optometry 2018; 101: 172-181.

[0253] 54. Kansteiner F. Apellis wins FDA approval for first geographic atrophy drug, https: / / www.fiercepharma.com / pharma / apellis-wins-fda-approval-first-geographic-atrophy-drug (2023).

[0254] 55. Gillies MC, Hunyor AP, Arnold JJ, et al. Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL study). Ophthalmology 2020; 127: 198-210.

[0255] 56. Daniel E, Maguire MG, Grunwald JE, et al. Incidence and progression of nongeographic atrophy in the comparison of age-related macular degeneration treatments trials (CATT) clinical trial. JAMA ophthalmology 2020; 138: 510-518.All documents and patents cited herein are incorporated herein by reference in their entirety. In addition, US Provisional Patent Application No. 63 / 800,231, filed May 5, 2025 is incorporated by reference in its entirety.

Claims

Claims1. A method of identifying, predicting, staging or prognosticating a disease of the macula in a subject, the method comprising the steps of:providing a first image of the retina of a subject to whom a labelled cell stress marker has been administered;identifying one or more labelled cell stress marker positive cells in that image; and assessing the arrangement of the one or more labelled cell stress marker positive cells using angular plot analysis.

2. The method of claim 1, wherein the stressed cells are cells that undergo stress in macular diseases.

3. The method of claim 1, wherein the stressed cells are photoreceptor cells.

4. The method of claim 1, wherein the disease of the macula is selected from Age- related Macular Degeneration (AMD), Stargardt Disease, Best Disease (Best Vitelliform Macular Dystrophy), Macular Telangiectasia Type 2 (MacTel 2), Cone- Rod Dystrophy, Pattern Dystrophies, Geographic Atrophy (GA), Chronic Central Serous Chorioretinopathy, Choroideremia, Gyrate Atrophy, Toxin based diseases such as Thioridazine Toxicity and Hydroxychloroquine Toxicity, and Advanced Retinitis Pigmentosa.

5. The method of claim 4, wherein the disease of the macula is AMD or GA.

6. The method of claim 1, wherein the cell stress marker is an annexin or a fragment or variant thereof.

7. The method of claim 6, wherein the annexin is selected from annexin 5, 11, 2 and 6.

8. The method of claim 1, wherein the label of the cell stress marker is a visible label.

9. The method of claim 8, wherein the label of the cell stress marker is fluorescent.

10. The method of claim 9, wherein the label of the cell stress marker has an emission wavelength of about 400nm to about lOOOnm.

11. The method of claim 1, wherein the label of the cell stress marker is one or more of sodium fluorescein, indocyanine green (ICG), curcumin, IRDye700, Dy-776 (which may otherwise be referred to as D-776), Dy- 488 and Dy-781.

12. The method of claim 1, wherein the disease is identified, predicted, staged or prognosticated, based on the number and / or position of stressed cells.

13. The method of claim 1, further comprising the step of step of identifying directional data about the one or more stressed cells identified, and relating that to progression of the disease of the macula.

14. The method of claim 1, further comprising the step of dividing the whole or part of the image of the retina into a plurality of segments.

15. The method of claim 14, wherein the step of identifying one or more labelled cell stress marker positive cells in that image comprises identifying the one or more stressed cells in each segment.

16. The method of claim 14, wherein the segments are angular segments arranged around a particular analysis point.

17. The method of claim 16, wherein the analysis point is a lesion, or a particular point on the retina, such as part of the macula, such as the fovea, especially the fovea centralis.

18. The method of claim 14, further comprising the step of totalling the number of stressed cells in each segment.

19. The method of claim 18, further comprising the step of plotting the total number of stressed cells in each segment in an angular plot.

20. The method of claim 19, further comprising the step of analysing the number and arrangement of segments in which stressed cells are found, and relating the number and arrangement to the presence, stage or prognosis of a disease of the macula.

21. The method of claim 1, wherein the identification of at least 5 cell stress marker positive cells in the image is indicative or predictive of the subject having or developing a disease of the macula, or indicative of the severity of that disease.

22. The method of claim 16, wherein the identification of at least 5 cell stress marker positive cells in the image, within about 0.01pm of the macula is predictive of the subject having or developing a disease of the macula and / or of the severity of that disease.

23. The method of claim 1, wherein the location of stressed cells identified in the image is indicative of the location or direction of growth of the disease of the macula.

24. The method of claim 1, wherein the identification of at least 5 cell stress marker positive cells in the image, in at least 2 of the 1° segments is having, or developing a disease of the macula, and / or of having an increased severity of disease.

25. The method of claim 1, further comprising the step of generating an image from the subject using an imaging device.

26. The method of claim 1, further comprising the step of administering a labelled cell stress marker to the subject.

27. The method of claim 1, further comprising the step administering an appropriate treatment for the disease, stage of disease, severity of disease or predicted disease identified.

28. The method of claim 1, further comprising the steps of:providing or generating second, third, fourth, fifth or further additional images; identifying one or more stressed cells in said image(s);assessing the arrangement of the one or more stressed cells using angular plot analysis; andcomparing the arrangement of the one or more stressed cells to one or more preceding arrangements of stressed cells in that subject.

29. A labelled cell stress marker for identifying, predicting, staging or prognosticating a disease of the macula in a subject, wherein the disease is identified, predicted, staged or prognosticated using the method of any of claims 1 to 24.